Frankfurt
22.07.25 | 09:59
8,650 Euro
-0,57 % -0,050
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 8,050 | 9,000 | 10:16 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| Do | ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma Announces Closing of Placement Shares in Top-Up Placement | 1 | GlobeNewswire (USA) | ||
| 15.07. | ASCENTAGE-B Slips 3.88% on Top-up Placement at 8.2% Discount to Raise HKD1.49B+ Net | 1 | AASTOCKS | ||
| 15.07. | ASCENTAGE-B (06855): PLACING OF EXISTING SHARES AND TOP-UP SUBSCRIPTION OF NEW SHARES UNDER GENERAL MANDATE | 1 | HKEx | ||
| 14.07. | Ascentage Pharma Prices Top-Up Placement At HKD68.60 Per Share | 1 | RTTNews | ||
| 14.07. | Ascentage Pharma announces $192.3 million share placement | 1 | Investing.com | ||
| ASCENTAGE PHARMA GROUP Aktie jetzt für 0€ handeln | |||||
| 14.07. | ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma Announces Pricing of Top-Up Placement | 1 | GlobeNewswire (USA) | ||
| 14.07. | ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma Announces Proposed Top-Up Placement | 3 | GlobeNewswire (USA) | ||
| 10.07. | ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma Announces Its Novel Bcl-2 Inhibitor Lisaftoclax Approved by China NMPA, Ushering in a New Era for the Treatment of CLL/SLL | 265 | GlobeNewswire (Europe) | ROCKVILLE, Md. and SUZHOU, China, July 10, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers... ► Artikel lesen | |
| 10.07. | ASCENTAGE-B (06855): VOLUNTARY ANNOUNCEMENT - NOVEL BCL-2 INHIBITOR LISAFTOCLAX APPROVED BY CHINA NMPA FOR TREATMENT OF ADULT CLL/SLL PATIENTS | - | HKEx | ||
| 08.07. | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 08.07. | Ascentage Pharma appoints Veet Misra as CFO | 1 | Seeking Alpha | ||
| 08.07. | ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma Appoints Dr. Veet Misra as Chief Financial Officer and Eric Huang as Senior Vice President of Global Corporate Development and Finance | 84 | GlobeNewswire (Europe) | ROCKVILLE, Md. and SUZHOU, China, July 07, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) ("Ascentage Pharma" or the "Company"), a global biopharmaceutical... ► Artikel lesen | |
| 03.07. | HSI Closes at 24,069, Down 151 pts; HSTI Closes at 5,233, Down 35 pts; XIAOMI Down over 3%; ZIJIN MINING, AKESO, KB LAMINATES, ASCENTAGE, GLOBAL NEW MAT Hit New Highs; Market Turnover Rises | 15 | AASTOCKS | ||
| 03.07. | HSI Closes Midday at 23,989, Down 232 pts; HSTI Closes Midday at 5,205, Down 63 pts; XIAOMI Down over 4%; BABA Down over 3%; HENDERSON LAND, XINYI ENERGY, ASCENTAGE, GLOBAL NEW MAT, GREAT EAGLE H Hit New Highs | 35 | AASTOCKS | ||
| 27.06. | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 27.06. | ASCENTAGE-B (06855): FURTHER GRANT OF AWARDS UNDER THE 2021 RSU SCHEME AND THE 2022 RSU SCHEME | - | HKEx | ||
| 16.06. | ASCENTAGE-B (06855): VOLUNTARY ANNOUNCEMENT - ASCENTAGE PHARMA RELEASES LATEST RESULTS FROM MULTIPLE CLINICAL STUDIES IN 2025 EUROPEAN HEMATOLOGY ASSOCIATION ... | - | HKEx | ||
| 16.06. | ASCENTAGE PHARMA GROUP INTERNATIONAL: EHA 2025 | Multiple Studies Report Encouraging Data of Olverembatinib in Ph+ ALL | 192 | GlobeNewswire (Europe) | ROCKVILLE, Md. and SUZHOU, China, June 15, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers... ► Artikel lesen | |
| 10.06. | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | - | SEC Filings |
1 2 3 4 5 Weiter >>
87 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| RECURSION PHARMACEUTICALS | 6,380 | 0,00 % | Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth? | ||
| EVOTEC | 6,240 | -16,31 % | Evotec, Hugo Boss, Lanxess, Nagarro, SMA Solar, Zalando - Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| ITEOS THERAPEUTICS | 10,135 | 0,00 % | iTeos Therapeutics Inc.: iTeos Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $10.047 in Cash per Share Plus a Contingent Value Right | WATERTOWN, Mass. and GOSSELIES, Belgium, July 21, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. ("iTeos") (Nasdaq: ITOS) today announced that it has entered into a definitive merger agreement... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 34,040 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD Participants | -- Unprecedented data from FORTITUDE dose escalation cohorts for del-brax treated participants, compared to placebo, demonstrate improvement in function, strength and PROs as well as rapid... ► Artikel lesen | |
| BEAM THERAPEUTICS | 21,020 | 0,00 % | Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress | Updated Data from 17 Patients Consistent with Previously Presented Data; All Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to Patients... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 26,340 | 0,00 % | Summit Therapeutics (SMMT) Climbs 16% Ahead of Q2 Earnings | ||
| SAB BIOTHERAPEUTICS | 2,655 | 0,00 % | SAB Biotherapeutics: Oppenheimer erhöht Kursziel auf 14 US-Dollar | ||
| REDHILL BIOPHARMA | 2,380 | 0,00 % | RedHill Biopharma Ltd.: RedHill Receives Positive FDA Feedback on Pathway to Approval of Groundbreaking RHB-204 for Crohn's Disease | The positive FDA feedback allows for:
A novel Phase 2 RHB-204[1] study, planned to be the first ever clinical study in a specifically defined Mycobacterium avium... ► Artikel lesen | |
| 180 LIFE SCIENCES | 2,800 | 0,00 % | 180 Life Sciences Corp. Announces Strengthening of Legacy Intellectual Property Assets | PALO ALTO, CA / ACCESS Newswire / July 1, 2025 / 180 Life Sciences Corp. (NASDAQ:ATNF) ("180" or the "Company), an innovative biotechnology company that is currently pivoting to the global iGaming sector... ► Artikel lesen | |
| ABSCI | 3,505 | 0,00 % | Absci Corporation: Absci Announces First Participants Dosed in Phase 1 Clinical Trial of ABS-101, a Potential Best-In-Class anti-TL1A Antibody for the Treatment of Inflammatory Bowel Disease | Absci becomes clinical stage company with ABS-101, first AI-designed biologic for IBD, beginning Phase 1 trial Preclinical data for ABS-101 demonstrates high potency and potential for quarterly dosing... ► Artikel lesen | |
| ADMA BIOLOGICS | 17,130 | +2,39 % | ADMA Biologics, Inc.: ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update | 1Q 2025 Total Revenue of $114.8 Million (Adjusted Total Revenue(1) of $118.6 Million), a 40% YoY Increase 1Q 2025 GAAP Net Income of $26.9 Million, a 51% YoY Increase 1Q 2025 Adjusted EBITDA(2) of... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 35,210 | +0,03 % | Truist Securities initiates Harmony Biosciences stock with Buy rating | ||
| KYMERA THERAPEUTICS | 45,140 | 0,00 % | Kymera Surges 70% in 3 Months: Buy, Sell or Hold the Stock? | ||
| VERVE THERAPEUTICS | 10,955 | +0,37 % | Verve Therapeutics sichert Führungskräfte mit Halteprämien vor Übernahme durch Eli Lilly | ||
| SANA BIOTECHNOLOGY | 4,450 | 0,00 % | Sana Biotechnology, Inc: Sana Biotechnology Announces Positive Six-Month Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression | Groundbreaking First-in-Human Study Establishes Potential to Treat Type 1 Diabetes by Transplanting Insulin-Secreting Cells Without Immunosuppression Six-Month Patient Follow-up Results Demonstrate... ► Artikel lesen |
Das Unternehmen ASCENTAGE PHARMA GROUP INTERNATIONAL kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -0,57 % bei einem Aktienkurs von 8,650 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ASCENTAGE PHARMA GROUP INTERNATIONAL finden Sie auf Wallstreet Online.